InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,100.00
(
2.07%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.61
(
0.05%
)
Bitcoin
66,514.94
(
0.16%
)
Post# of 75087
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Screech691

Send PM Follow Ignore
Followers 822
Posts 163135
Boards Moderated 6
Alias Born 09/23/2009

Screech691

Re: None

Thursday, 01/19/2017 10:43:03 AM

Thursday, January 19, 2017 10:43:03 AM

Post# of 75087
$IMLFF After making significant progress in 2016, the company is finalizing the transdermal formulation for its Epidermolysis Bullosa (EB) therapy and plans to complete toxicology testing in 2017. The team plans to begin clinical trials in 2018 and will seek an expedited review process with regulatory authorities, including the U.S. FDA, to minimize this product's time-to-market.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up